Literature DB >> 18951619

Clinical and molecular profile of a new series of patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: inconsistent correlation between forkhead box protein 3 expression and disease severity.

Eleonora Gambineri1, Lucia Perroni, Laura Passerini, Lucia Bianchi, Claudio Doglioni, Franco Meschi, Riccardo Bonfanti, Yves Sznajer, Alberto Tommasini, Anita Lawitschka, Anne Junker, Desiree Dunstheimer, Peter H Heidemann, Giantonio Cazzola, Marco Cipolli, Wilhelm Friedrich, Dragana Janic, Nadira Azzi, Erick Richmond, Silvia Vignola, Arrigo Barabino, Giuseppe Chiumello, Chiara Azzari, Maria-Grazia Roncarolo, Rosa Bacchetta.   

Abstract

BACKGROUND: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome is an autoimmune genetic disorder caused by mutation of the forkhead box protein 3 gene (FOXP3), a key regulator of immune tolerance.
OBJECTIVE: We sought to provide clinical and molecular indicators that facilitate the understanding and diagnosis of IPEX syndrome.
METHODS: In 14 unrelated affected male subjects who were given diagnoses of IPEX syndrome based on FOXP3 gene sequencing, we determined whether particular FOXP3 mutations affected FOXP3 protein expression and correlated the molecular and clinical data.
RESULTS: Molecular analysis of FOXP3 in the 14 subjects revealed 13 missense and splice-site mutations, including 7 novel mutations. Enteropathy, generally associated with endocrinopathy and eczema, was reported in all patients, particularly in those carrying mutations within FOXP3 functional domains or mutations that altered protein expression. However, similar genotypes did not always result in similar phenotypes in terms of disease presentation and severity. In addition, FOXP3 protein expression did not correlate with disease severity.
CONCLUSION: Severe autoimmune enteropathy, which is often associated with increased IgE levels and eosinophilia, is the most prominent early manifestation of IPEX syndrome. Nevertheless, the disease course is variable and somewhat unpredictable. Therefore genetic analysis of FOXP3 should always be performed to ensure an accurate diagnosis, and FOXP3 protein expression analysis should not be the only diagnostic tool for IPEX syndrome.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18951619     DOI: 10.1016/j.jaci.2008.09.027

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  59 in total

Review 1.  Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases.

Authors:  Lisa M Kosloski; Duy M Ha; Jessica A L Hutter; David K Stone; Michael R Pichler; Ashley D Reynolds; Howard E Gendelman; R Lee Mosley
Journal:  J Neurochem       Date:  2010-05-26       Impact factor: 5.372

2.  Immune Dysregulation Syndromes (IPEX, CD27 Deficiency, and Others): Always Doomed from the Start?

Authors:  Markus G Seidel; Kaan Boztug; Oskar A Haas
Journal:  J Clin Immunol       Date:  2015-12-10       Impact factor: 8.317

3.  Fatal autoimmunity in mice reconstituted with human hematopoietic stem cells encoding defective FOXP3.

Authors:  Jeremy A Goettel; Subhabrata Biswas; Willem S Lexmond; Ada Yeste; Laura Passerini; Bonny Patel; Siyoung Yang; Jiusong Sun; Jodie Ouahed; Dror S Shouval; Katelyn J McCann; Bruce H Horwitz; Diane Mathis; Edgar L Milford; Luigi D Notarangelo; Maria-Grazia Roncarolo; Edda Fiebiger; Wayne A Marasco; Rosa Bacchetta; Francisco J Quintana; Sung-Yun Pai; Christoph Klein; Aleixo M Muise; Scott B Snapper
Journal:  Blood       Date:  2015-04-01       Impact factor: 22.113

4.  Single centre experience of haematopoietic SCT for patients with immunodysregulation, polyendocrinopathy, enteropathy, X-linked syndrome.

Authors:  Z Nademi; M Slatter; E Gambineri; S C Mannurita; D Barge; S Hodges; S Bunn; J Thomas; B Haugk; S Hambleton; T Flood; A Cant; M Abinun; A Gennery
Journal:  Bone Marrow Transplant       Date:  2013-11-25       Impact factor: 5.483

Review 5.  Regulatory T cells exert checks and balances on self tolerance and autoimmunity.

Authors:  Kajsa Wing; Shimon Sakaguchi
Journal:  Nat Immunol       Date:  2009-12-17       Impact factor: 25.606

Review 6.  Evaluation and differential diagnosis of marked, persistent eosinophilia.

Authors:  Rojelio Mejia; Thomas B Nutman
Journal:  Semin Hematol       Date:  2012-04       Impact factor: 3.851

7.  Accumulation of peripheral autoreactive B cells in the absence of functional human regulatory T cells.

Authors:  Tuure Kinnunen; Nicolas Chamberlain; Henner Morbach; Jinyoung Choi; Sangtaek Kim; Joseph Craft; Lloyd Mayer; Caterina Cancrini; Laura Passerini; Rosa Bacchetta; Hans D Ochs; Troy R Torgerson; Eric Meffre
Journal:  Blood       Date:  2012-12-05       Impact factor: 22.113

Review 8.  Advances in basic and clinical immunology in 2008.

Authors:  Javier Chinen; William T Shearer
Journal:  J Allergy Clin Immunol       Date:  2009-02       Impact factor: 10.793

9.  Regulation and dysregulation of immunoglobulin E: a molecular and clinical perspective.

Authors:  Mariah B Pate; John Kelly Smith; David S Chi; Guha Krishnaswamy
Journal:  Clin Mol Allergy       Date:  2010-02-23

Review 10.  Empowering Regulatory T Cells in Autoimmunity.

Authors:  Isaac R Kasper; Sokratis A Apostolidis; Amir Sharabi; George C Tsokos
Journal:  Trends Mol Med       Date:  2016-07-25       Impact factor: 11.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.